AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36056778
Drug: Ruxolitinib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (25 mg orally twice daily in continuous 28-day cycles)
Trial: 33105861
Drug: Kudzu flower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kudzu flower and mandarin peel extract (KM) 1150 mg/day
Trial: 35368058
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg biweekly for 52 weeks)
Trial: 32434975
Drug: Controlled-release drugs
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release drugs - chlorhexidine gel
Trial: 34918443
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg.kg-1)
Trial: 34918443
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg.kg-1)
Trial: 35789991
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (60,000 international units monthly for 5 years)
Trial: 35789991
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (60,000 international units monthly for 5 years) in adults aged ≥70 years
Trial: 33372392
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 1000 IU and Calcium 1000 mg daily for 6 weeks (Group A)
Trial: 33372392
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 250 IU and Calcium 500 mg daily for 6 weeks (Group B)
Trial: 32525863
Drug: Routine enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine enteral nutrition (1kcal/mL)
Trial: 32501612
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for type 2 diabetes (specific treatments not detailed)
Trial: 34231281
Drug: gel vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel vehicle
Trial: 33856355
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy
Trial: 36795388
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (control)
Trial: 32763021
Drug: Ketamine (0.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.44 mg/kg intravenous dose)
Trial: 34717750
Drug: Video Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video Intervention Therapy (VIT)
Trial: 34161146
Drug: Flaxseed (40-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40-g packets daily before and during radiotherapy)
Trial: 36104059
Drug: ESPB (Erector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB (Erector Spinae Plane Block) with 20 mL of 0.25% bupivacaine
Trial: 34606560
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (540 mg GLA per day)
Trial: 35438442
Drug: eHealth Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Trial: 33439215
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of risk factors (high SES, low PRS)
Trial: 33439215
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of risk factors (high PRS, parental history)
Trial: 36625789
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate
Trial: 33567780
Drug: Spirulina maxima
RxNorm normalized name: SPIRULINA MAXIMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina maxima intake (5 g/day)
Trial: 32107871
Drug: Home titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home titration using an APAP device for three days
Trial: 32107871
Drug: Laboratory attended
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory attended APAP titration
Trial: 32370596
Drug: Antibody 1
RxNorm normalized name: Blood group antibody 1123K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody 1
Trial: 32370596
Drug: Antibody 2
RxNorm normalized name: Monoclonal Antibody 2C4
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody 2
Trial: 32370596
Drug: Antibody 3
RxNorm normalized name: MONOCLONAL ANTIBODY 3F8
DrugBank: Anti-GD2 monoclonal antibody 3F8 (DB15388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody 3
Trial: 32370596
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three antibodies
Trial: 39527516
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) intervention
Trial: 35508008
Drug: Inhaled ciclesonide
RxNorm normalized name: ciclesonide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ciclesonide + placebo
Trial: 35843914
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg during induction)
Trial: 35843914
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (1.5 gr/hr as continuous intravenous infusion after intubation)
Trial: 35843914
Drug: Fentanyl (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (bolus doses during surgery)
Trial: 33407599
Drug: Whole tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole tomato food supplement (WTFS)
Trial: 35713160
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus 20 g vitamin C once daily (1-10 days) and 500 mg twice daily (11-100 days)
Trial: 35690931
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HiRIT and medication
Trial: 32085539
Drug: Monthly budget
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly budget
Trial: 37004331
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (OAP)
Trial: 35247794
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (OAP/OAP)
Trial: 35247794
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (OAP/PP)
Trial: 32448257
Drug: 800mcg sublingual
RxNorm normalized name: ABSTRAL 800mcg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mcg sublingual misoprostol given only to women with 350-500 ml postpartum blood loss (secondary prevention)
Trial: 33411992
Drug: Prefilled syringe
RxNorm normalized name: Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefilled syringe (fremanezumab 225 mg)
Trial: 36326117
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of RAS inhibitors
Trial: 33872601
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone injected into gluteal muscle
Trial: 33872601
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone injected into masseter muscle
Trial: 35017010
Drug: Intravenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GLP-1 infusion (2.5 pmol/kg/min)
Trial: 33939911
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (group 3)
Trial: 34391744
Drug: Transcatheter mitral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter mitral valve repair (TMVr) plus guideline-directed medical therapy (GDMT)
Trial: 35852098
Drug: Venetoclax in
RxNorm normalized name: Product containing venetoclax in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax in combination with oral azacitidine (CC‐486) as maintenance therapy
Trial: 32791894
Drug: Olanzapine/samidorphan combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/samidorphan combination
Trial: 33009729
Drug: Antivirals or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antivirals or treatment of complications (specifics not provided)
Trial: 35577631
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg +/‐ CpG1018
Trial: 35577631
Drug: 3 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 μg alone
Trial: 33298104
Drug: Diluted maple
RxNorm normalized name: coast maple pollen extract
DrugBank: Acer macrophyllum pollen (DB10734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted maple syrup (MS)
Trial: 33304282
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg THC
Trial: 33517882
Drug: Additional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional daily physical therapy focused on mobility (n=99)
Trial: 33517882
Drug: Additional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional daily physical therapy focused on mobility
Trial: 32956615
Drug: Supportive care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care, intravenous immunoglobulin, methylprednisolone, biological therapies (IL-1 antagonists, IL-6 receptor blockers, anti-TNF agents)
Trial: 32956615
Drug: IL-1 antagonists
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 antagonists (e.g., anakinra), IL-6 receptor blockers (e.g., tocilizumab), anti-TNF agents (e.g., infliximab)
Trial: 32956615
Drug: New PIMS-TS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New PIMS-TS specific treatment groups
Trial: 32484940
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 200 μg/d
Trial: 32484940
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) high doses (≥1000 μg BID)
Trial: 32484940
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) high doses (≥1500 μg BID)
Trial: 36107516
Drug: Dance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance therapy using telerehabilitation (n = 9)
Trial: 36107516
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (n = 8)
Trial: 34363617
Drug: Prochlorperazine 10
RxNorm normalized name: prochlorperazine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 10 mg IV plus diphenhydramine 25 mg IV
Trial: 34515993
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy
Trial: 34642762
Drug: Free amino
RxNorm normalized name: FREE AMINO ACID DIET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free amino acids (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Trial: 34642762
Drug: Intact milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact milk protein (30 g intrinsically l-[1-13C]-phenylalanine-labeled)
Trial: 36253339
Drug: Infant massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant massage (5 weeks, daily for at least 10 minutes)
Trial: 36872873
Drug: Standard-of-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapy
Trial: 38445295
Drug: Berotralstat 150
RxNorm normalized name: berotralstat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotralstat 150 mg
Trial: 33098856
Drug: Berotralstat 110
RxNorm normalized name: berotralstat 110 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotralstat 110 mg
Trial: 33220855
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 (standard-dose)
Trial: 33220855
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 (single standard dose)
Trial: 34816288
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (early-PN)
Trial: 32260466
Drug: Schisandra Chinensis
RxNorm normalized name: SCHISANDRA CHINENSIS SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schisandra Chinensis extract (1000 mg per day)
Trial: 33106171
Drug: Melatonin capsules
RxNorm normalized name: melatonin Oral Capsule
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin capsules at a dose of 50 mg daily for a period of seven days
Trial: 33106171
Drug: Melatonin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin and standard treatment
Trial: 33106171
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and standard treatment
Trial: 33709288
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy
Trial: 36458679
Drug: Desidustat 50
RxNorm normalized name: Desidustat
DrugBank: Desidustat (DB16135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desidustat 50 mg orally in a fed state
Trial: 34494517
Drug: Ultra-fast track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-fast track cardiac anaesthesia (Group D) with dexmedetomidine at 1 ?g/kg/hour and sufentanil for analgesia
Trial: 35148706
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) counseling
Trial: 35833334
Drug: Erythropoietin (ESA)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (ESA) treatment
Trial: 37400931
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron treatment
Trial: 35662232
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg/d for 12 weeks
Trial: 38325518
Drug: Individual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual and Group Supportive Therapy (IGST)
Trial: 35360477
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic nursing
Trial: 35572982
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy alone for 4 months
Trial: 34587371
Drug: Liposomal cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal cyclosporine A for inhalation (L‐CsA‐i) administered twice daily via nebulizer for 2 years
Trial: 34587371
Drug: Liposomal cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal cyclosporine A for inhalation (L‐CsA‐i) administered to SLT recipients
Trial: 35653577
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac 30 mg
Trial: 33351126
Drug: Polyvalent immunoglobulin
RxNorm normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent immunoglobulin preparation
Trial: 33351126
Drug: Pneumolysin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumolysin treatment
Trial: 34185723
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL 0.5% ropivacaine (low-volume STB)
Trial: 34185723
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL 0.5% ropivacaine (standard-volume STB)
Trial: 37079569
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies
Trial: 32131077
Drug: Smartphone overdependence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone overdependence prevention program (8 sessions, twice a week)
Trial: 33788599
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT); n=46, 12 weekly 90-min group sessions.
Trial: 32966971
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro plus glargine
Trial: 32576561
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with exenatide (2 mg/week) and pioglitazone (30 mg/day)
Trial: 32576561
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin (glargine with aspart)
Trial: 36056908
Drug: Ultrasound-guided capsular
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided capsular injection of dexamethasone (DEX) and lidocaine
Trial: 32104059
Drug: Intravenous steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous steroids
Trial: 32838647
Drug: standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard dose regimen (tenofovir disoproxil 200 mg, efavirenz 600 mg and lamivudine)
Trial: 32838647
Drug: lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lower dose regimen (tenofovir disoproxil 200 mg, efavirenz 400 mg and lamivudine)
Trial: 33217193
Drug: Sorafenib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib therapy
Trial: 33781142
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg
Trial: 32876962
Drug: Low frequent
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low frequent high dosage IVIg treatment
Trial: 34927594
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) (control group)
Trial: 35863457
Drug: Oteseconazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oteseconazole (600 mg on day 1 and 450 mg on day 2)
Trial: 35863457
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 sequential 150-mg doses every 72 hours)
Trial: 35863457
Drug: Oteseconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oteseconazole (150 mg weekly for 11 weeks)
Trial: 35863457
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 mg weekly for 11 weeks)
Trial: 33473019
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: 36654288
Drug: Bumetanide 0.5
RxNorm normalized name: bumetanide 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 0.5 mg
Trial: 35193441
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction (DR) of adalimumab
Trial: 35193441
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction (DR) of ustekinumab
Trial: 35193441
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction (DR) of etanercept
Trial: 35945733
Drug: Acupuncture, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture, administered twice a week for 6 weeks (total of 12 sessions) on 9 defined acupuncture points.
Trial: 35945733
Drug: Thread embedding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thread embedding acupuncture (TEA), administered once a week for 6 weeks (total of 6 sessions) on 14 defined knee areas.